Development of the Berlin Symptom Checklist Ovary (BSCL-O) for the measurement of quality of life of patients with primary and recurrent ovarian cancer: Results of a phase I and II study

Supportive Care in Cancer

Volumn 18, Issue 8, 2010, Pages 931-942

  Koensgen, Dominique ^a   Oskay Oezcelik, Guelten ^c   Katsares, Ioanna ^b   Walle, Ulla ^c   Klapp, Christine ^c   Mustea, Alexander ^a   Stengel, Dirk ^d   Porzsolt, Franz ^e   Lichtenegger, Werner ^c   Sehouli, Jalid ^c  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b KLINIKUM BREMEN MITTE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNFALLKRANKENHAUS BERLIN   (Germany)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

Instruments of measurement; Ovarian cancer; Quality of life

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BENIGN TUMOR; BERLIN SYMPTOM CHECKLIST OVARY; BREAST METASTASIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; PROCESS DEVELOPMENT; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT CANCER; VALIDATION PROCESS;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GERMANY; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 77956457683     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0733-0     Document Type: Article

References (22)

1. Anderson B (1994) Quality of life in progressive ovarian cancer. Gynecol Oncol 55:151-155
2. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA et al (2001) Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 19 (6):1809-1817
3. Bullinger M (1996) Methoden zur Lebensqualitätsbewertung in der Onkologie. Forum Deutsche Krebsgesellschaft 11:210-216
4. Calhoun EA, Welshman EE, Chang CH et al (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13 (6):741-748
5. Cella DF, Tulsky DS, Gray G et al (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570-579
6. Coates A, Dillenbeck CF, McNeil DR et al (1983) On the receiving end-II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving therapy. Eur J Cancer Clin Oncol 1 19:1633-1637
7. Cull A, Howat S, Greimel E et al (2001) Development of a European organization for research and treatment of cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 37:47-53
8. Ersek M, Ferrell B, Dow K et al (1997) Quality of life in women with ovarian cancer. West J Nurs Res 19:334-350 (Pubitemid 127459711)
9. Fish L, Lewis B (1999) Quality of life issues in the management of ovarian cancer. Semin Oncol 26:32-39
10. Greimel ER, Bjelic-Radisic V, Pfisterer J et al (2006) Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 24 (4):579-586
11. Greimel E, Bottomley A, Cull A et al (2003) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 39:1402-1408
12. Guidozzi F (1993) Living with ovarian cancer. Gynecol Oncol 50:202-207
13. Jacobs I, van Nagell J, De Priest P Jr (1998) Screening for epithelial ovarian cancer. In: David M, Gershenson W, McGuire P (eds) Ovarian cancer: controversies in management. Medical Division of Pearson Professional Limited, New York, pp 1-15
14. Le T, Leis A, Pahwa P et al (2004) Quality of life evaluations of caregivers of ovarian cancer patients during chemotherapy treatment. J Obstet Gynaecol Can 26 (7):627-631
15. Montazeri A, McEwen J, Gillis C (1996) Quality of life in patients with ovarian cancer: current state of research. Support Care Cancer 4:169-179
16. Moore DH (1994) Ovarian cancer in the elderly patient. Oncology (Williston Park) 8:21-30
17. Oskay-Ozcelik G, Sehouli J (2009) Pros and cons for systemic therapy in recurrent ovarian cancer. Anticancer Res 29 (7):2831-2836
18. Portenoy R, Kornblith A, Wong G (1994) Pain in ovarian cancer patients. Cancer 74:907-915
19. Portenoy R, Thaler H, Kornblith A (1994) The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30 A: 1326-1336
20. Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219-227
21. Wenzel L, Huang HQ, Monk BJ et al (2005) Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 23 (24):5605-5612
22. Willemse P, van Lith J, Mulder N (1990) Risk and benefits of cisplatin in ovarian cancer. A quality-adjusted survival analysis. Eur J Cancer 26:345-352